Molecular therapy for Human Leukemias: NR2F2 suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 7/October/2014, 14.40

Differentiation therapy for Human Leukaemia: Resistin functions as an anti-cancer barrier by promoting differentiation of leukaemic cells via up regulation of Histone methyl-transferase MLL4, 7/October/2014, 12.30 pm
October 7, 2014
Anti-cancer stem cell therapeutics: Tumor suppressor ING1b inhibits mammary cancer stem cell proliferation via down regulation of Wnt receptor FZD7, 7/October/2014, 14.53
October 7, 2014
Show all

The 1975 Nobel laureate in Physiology/Medicine Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 Blood that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid ….leukemias.” 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy  for Human Leukemias: NR2F2 suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4This study suggests that NR2F2, by increasing the expression of  its target gene, it could increase the expression of a number of tumor suppressor genes, including IRF4 and p53. Thereby, it could inhibit the progression of B-Cell and myeloid leukemias. Taken together, this study suggests that pharmacological formulations encompassing “NR2F2 or its activators” can be used to inhibit B-Cell and myeloid leukemias.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, L., Molecular therapy for Human Leukemias: NR2F2 suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 7/October/2014, 14.40,  Genome-2-Bio-Medicine Discovery Center.

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.